Cytokines and growth factors stimulate hyaluronan production: Role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Mulshine, James L ^a   Chow, Geraldine ^a   Tauler, Jordi ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GEFITINIB; GELATINASE A; GELATINASE B; HYALURONIC ACID; INTERLEUKIN 1BETA; UVOMORULIN; VIMENTIN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCURONOSYLTRANSFERASE; HAS3 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SIGNAL PEPTIDE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MESENCHYME CELL; PHENOTYPE; PROTEIN EXPRESSION; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MESODERM; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYTOKINES; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-1BETA; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESODERM; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77955398945     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/485468     Document Type: Article

References (58)

1. Greenlee R. T., Murray T., Bolden S., Wingo P. A., Cancer statistics, 2000 CA: A Cancer Journal for Clinicians 2000 50 1 7 33
2. Pirinen R., Tammi R., Tammi M., Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma International Journal of Cancer 2001 95 1 12 17
3. Toole B. P., Hyaluronan: from extracellular glue to pericellular cue Nature Reviews Cancer 2004 4 7 528 539
4. Itano N., Kimata K., Mammalian hyaluronan synthases IUBMB Life 2002 54 4 195 199
5. Weigel P. H., Hascall V. C., Tammi M., Hyaluronan synthases Journal of Biological Chemistry 1997 272 22 13997 14000
6. Itano N., Sawai T., Yoshida M., Lenas P., Yamada Y., Imagawa M., Shinomura T., Hamaguchi M., Yoshida Y., Ohnuki Y., Miyauchi S., Spicer A. P., McDonald J. A., Kimata K., Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties Journal of Biological Chemistry 1999 274 35 25085 25092
7. Adamia S., Maxwell C. A., Pilarski L. M., Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer Current Drug TargetsCardiovascular and Haematological Disorders 2005 5 1 3 14
8. Berdiaki A., Zafiropoulos A., Fthenou E., Katonis P., Tsatsakis A., Karamanos N. K., Tzanakakis G. N., Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines Biochimica et Biophysica Acta 2008 1780 2 194 202
9. Tzanakakis G. N., Karamanos N. K., Hjerpe A., Effects on glycosaminoglycan synthesis in cultured human mesothelioma cells of transforming, epidermal, and fibroblast growth factors and their combinations with platelet-derived growth factor Experimental Cell Research 1995 220 1 130 137
10. Bourguignon L. Y. W., Gilad E., Peyrollier K., Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration Journal of Biological Chemistry 2007 282 27 19426 19441
11. Anttila M. A., Tammi R. H., Tammi M. I., Syrjnen K. J., Saarikoski S. V., Kosma V.-M., High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer Cancer Research 2000 60 1 150 155
12. Auvinen P., Tammi R., Parkkinen J., Tammi M., Agren U., Johansson R., Hirvikoski P., Eskelinen M., Kosma V.-M., Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival American Journal of Pathology 2000 156 2 529 536
13. Kimata K., Honma Y., Okayama M., Oguri K., Hozumi M., Suzuki S., Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential Cancer Research 1983 43 3 1347 1354
14. Asplund T., Versnel M. A., Laurent T. C., Heldin P., Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts Cancer Research 1993 53 2 388 392
15. Kosaki R., Watanabe K., Yamaguchi Y., Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity Cancer Research 1999 59 5 1141 1145
16. Liu N., Gao F., Han Z., Xu X., Underhill C. B., Zhang L., Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells Cancer Research 2001 61 13 5207 5214
17. Jacobson A., Rahmanian M., Rubin K., Heldin P., Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors International Journal of Cancer 2002 102 3 212 219
18. Itano N., Sawai T., Miyaishi O., Kimata K., Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells Cancer Research 1999 59 10 2499 2504
19. Simpson M. A., Wilson C. M., McCarthy J. B., Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice American Journal of Pathology 2002 161 3 849 857
20. Udabage L., Brownlee G. R., Waltham M., Blick T., Walker E. C., Heldin P., Nilsson S. K., Thompson E. W., Brown T. J., Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer Cancer Research 2005 65 14 6139 6150
21. Bourguignon L. Y. W., Peyrollier K., Gilad E., Brightman A., Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to -catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells Journal of Biological Chemistry 2007 282 2 1265 1280
22. Ohwada C., Nakaseko C., Koizumi M., Takeuchi M., Ozawa S., Naito M., Tanaka H., Oda K., Cho R., Nishimura M., Saito Y., CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells European Journal of Haematology 2008 80 3 245 250
23. Ohashi R., Takahashi F., Cui R., Yoshioka M., Gu T., Sasaki S., Tominaga S., Nishio K., Tanabe K. K., Takahashi K., Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell Cancer Letters 2007 252 2 225 234
24. Alaniz L., Garca M., Cabrera P., Arnaiz M., Cavaliere V., Blanco G., Alvarez E., Hajos S., Modulation of matrix metalloproteinase-9 activity by hyaluronan is dependent on NF-κB activity in lymphoma cell lines with dissimilar invasive behavior Biochemical and Biophysical Research Communications 2004 324 2 736 743
25. Zhang Y., Thant A. A., Machida K., Ichigotani Y., Naito Y., Hiraiwa Y., Senga T., Sohara Y., Matsuda S., Hamaguchi M., Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90 Cancer Research 2002 62 14 3962 3965
26. Thiery J. P., Epithelial-mesenchymal transitions in tumor progression Nature Reviews Cancer 2002 2 6 442 454
27. Hugo H., Ackland M. L., Blick T., Lawrence M. G., Clements J. A., Williams E. D., Thompson E. W., Epithelialmesenchymal and mesenchymalepithelial transitions in carcinoma progression Journal of Cellular Physiology 2007 213 2 374 383
28. Bremnes R. M., Veve R., Hirsch F. R., Franklin W. A., The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis Lung Cancer 2002 36 2 115 124
29. Deeb G., Wang J., Ramnath N., Slocum H. K., Wiseman S., Beck A., Tan D., Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry Modern Pathology 2004 17 4 430 439
30. Loric S., Paradis V., Gala J.-L., Berteau P., Bedossa P., Benoit G., Eschwge P., Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer European Journal of Cancer 2001 37 12 1475 1481
31. Ray M. E., Mehra R., Sandler H. M., Daignault S., Shah R. B., E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes Journal of Urology 2006 176 4 1409 1414
32. Hegymegi-Barakonyi B., Eros D., Szntai-Kis C., Breza N., Bnhegyi P., Szab G. V., Vrkondi E., Petk I., Orfi L., Kri G., Tyrosine kinase inhibitorssmall molecular weight compounds Inhibiting EGFR Current Opinion in Molecular Therapeutics 2009 11 3 308 321
33. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., Iwata K. K., Gibson N., Haley J. D., Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Research 2005 65 20 9455 9462
34. Yauch R. L., Januario T., Eberhard D. A., Cavet G., Zhu W., Fu L., Pham T. Q., Soriano R., Stinson J., Seshagiri S., Modrusan Z., Lin C.-Y., O'Neill V., Amler L. C., Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients Clinical Cancer Research 2005 11 24 8686 8698
35. Frederick B. A., Helfrich B. A., Coldren C. D., Zheng D., Chan D., Bunn P. A. Jr., Raben D., Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma Molecular Cancer Therapeutics 2007 6 6 1683 1691
36. Haddad Y., Choi W., McConkey D. J., Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines Clinical Cancer Research 2009 15 2 532 542
37. Witta S. E., Gemmill R. M., Hirsch F. R., Coldren C. D., Hedman K., Ravdel L., Helfrich B., Dziadziuszko R., Chan D. C., Sugita M., Chan Z., Baron A., Franklin W., Drabkin H. A., Girard L., Gazdar A. F., Minna J. D., Bunn P. A. Jr., Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Research 2006 66 2 944 950 (Pubitemid 43165962)
38. Camenisch T. D., Spicer A. P., Brehm-Gibson T., Biesterfeldt J., Augustine M. L., Calabro A. Jr., Kubalak S., Klewer S. E., McDonald J. A., Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme Journal of Clinical Investigation 2000 106 3 349 360
39. Zoltan-Jones A., Huang L., Ghatak S., Toole B. P., Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells Journal of Biological Chemistry 2003 278 46 45801 45810
40. Xu Y., Yu Q., E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis Journal of Biological Chemistry 2003 278 10 8661 8668
41. Knudson C. B., Hyaluronan receptor-directed assembly of chondrocyte pericellular matrix Journal of Cell Biology 1993 120 3 825 834
42. Peebles K. A., Lee J. M., Mao J. T., Hazra S., Reckamp K. L., Krysan K., Dohadwala M., Heinrich E. L., Walser T. C., Cui X., Baratelli F. E., Garon E., Sharma S., Dubinett S. M., Inflammation and lung carcinogenesis: applying findings in prevention and treatment Expert Review of Anticancer Therapy 2007 7 10 1405 1421
43. Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y., Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K., Yasumoto K., Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro Cancer Science 2007 98 7 1048 1054
44. Wang M., Wang T., Liu S., Yoshida D., Teramoto A., The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades Brain Tumor Pathology 2003 20 2 65 72
45. Chambers A. F., Matrisian L. M., Changing views of the role of matrix metalloproteinases in metastasis Journal of the National Cancer Institute 1997 89 17 1260 1270
46. Grandis J. R., Sok J. C., Signaling through the epidermal growth factor receptor during the development of malignancy Pharmacology and Therapeutics 2004 102 1 37 46
47. Akita R. W., Sliwkowski M. X., Preclinical studies with erlotinib (Tarceva) Seminars in Oncology 2003 30 3 15 24
48. Normanno N., Bianco C., De Luca A., Salomon D. S., The role of EGF-related peptides in tumor growth Frontiers in Bioscience 2001 6 685 707
49. Matani D., Beg-Zec Z., Stojanovi D., Matakori-Mileusni N., Flego V., Milevoj-Ribi F., Dubravka M., Cytokines in patients with lung cancer Scandinavian Journal of Immunology 2003 57 2 173 178
50. Hasegawa Y., Takanashi S., Kanehira Y., Tsushima T., Imai T., Okumura K., Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinom Cancer 2001 91 5 964 971
51. Jacobson A., Brinck J., Briskin M. J., Spicer A. P., Heldin P., Expression of human hyaluronan syntheses in response to external stimuli Biochemical Journal 2000 348 1 29 35
52. Toole B. P., Hyaluronan in morphogenesis Seminars in Cell and Developmental Biology 2001 12 2 79 87
53. Kris M. G., Natale R. B., Herbst R. S., Lynch T. J. Jr., Prager D., Belani C. P., Schiller J. H., Kelly K., Spiridonidis H., Sandler A., Albain K. S., Cella D., Wolf M. K., Averbuch S. D., Ochs J. J., Kay A. C., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial Journal of the American Medical Association 2003 290 16 2149 2158 (Pubitemid 37432975)
54. Shepherd F. A., Pereira J. R., Ciuleanu T., Eng H. T., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., Van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabrbara P., Seymour L., Erlotinib in previously treated non-small-cell lung cancer The New England Journal of Medicine 2005 353 2 123 132 (Pubitemid 41058344)
55. Fukuoka M., Yano S., Giaccone G., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) Journal of Clinical Oncology 2003 21 12 2237 2246
56. Tsao M.-S., Sakurada A., Cutz J.-C., Zhu C.-Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., Daneshmand M., Marrano P., Da Cunha Santos G., Lagarde A., Richardson F., Seymour L., Whitehead M., Ding K., Pater J., Shepherd F. A., Erlotinib in lung cancermolecular and clinical predictors of outcome The New England Journal of Medicine 2005 353 2 133 144
57. Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., Brannigan B. W., Harris P. L., Haserlat S. M., Supko J. G., Haluska F. G., Louis D. N., Christiani D. C., Settleman J., Haber D. A., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine 2004 350 21 2129 2139
58. Thomson S., Petti F., Sujka-Kwok I., Epstein D., Haley J. D., Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy Clinical and Experimental Metastasis 2008 25 8 843 854